Giampero (John) A. Martignetti, MD, PhD
The road of research in gynecologic malignancies needs to take a turn toward improved detection methods and classification, experts say, in order to both understand the biology of a patient’s tumor, as well as the biology of mutations they may harbor that are not driving the cancer.
on Treatment Options in Ovarian Cancer, Martignetti, a professor of genetics and genomic sciences, oncological sciences, obstetrics, gynecology and reproductive science, and pediatrics at Mount Sinai School of Medicine, discussed evolving methods to detect gynecologic malignancies, with a focus on fallopian tube cancer.
OncLive: What did you share in your overview on fallopian tube cancer?
: The talk really focused on detection methods in gynecologic ovarian cancers, specifically, and trying to stress the history of how we got to where we are in detecting cancers, how to think about what it means to detect them, and some of the technology that goes on behind the scenes in detecting these cancers. It is primarily focused on circulating tumor (ct) DNA.
How has this type of technology evolved in recent years?
The one thing that I also wanted to get across in the talk was the concept that this is a brave new world, in the sense that next-generation sequencing technologies have really changed what we can see. In the past, we have relied on x-rays, clinical exam x-rays, CT scans, but now the level of detail that we are getting is unheralded. That can be both a good thing and be pretty scary, too.
... to read the full story